The National Anti-Doping Panel (NADP) has delivered a verdict in the UK Anti-Doping (UKAD) case against Ashley Calvert.
On 18 November 2022 UKAD issued a Notice of Charge to Mr Calvert, a National Level ice hockey player, for committing Anti-Doping Rule Violations (ADRVs) due to the presence and Use of prohibited substances of morphine and/or oxycodone; and/or oxymorphone on or before 05 December 2021.
Ms Michelle Duncan (President), Ms Lorraine Johnson and Dr. The National Anti-Doping Tribunal, composed of Neil Townshend, was commissioned to set this issue on the documents.
Adverse analytical findings resulted from In-Competition doping control testing performed during the Blackburn Hawks vs Solihull Barons match at Blackburn Ice Arena on December 5, 2021. Morphine, oxycodone and oxymorphone are classified as Narcotics in section S7 of the 2021 WADA Prohibited List. These are Specified Items Prohibited During Competition only. Mr. Calvert did not have a valid or valid TUE to justify the Specified Substances in his Sample. The UKAD has found, to the Court’s comfortable satisfaction, that Mr Calvert had committed ADRVs pursuant to ADR Article 2.1 and ADR Article 2.2 and did not seek to establish that the ADRVs were intentional. Pursuant to ADR Article 10.9.4(a), Penalties will be treated as a single ADRV for sanctioning purposes.
Accordingly, the Court is satisfied that Mr Calvert had committed ADRVs under Articles 2.1 and 2.2 of ADR and ordered a period of Ineligibility of two years. The sanction will retroactively begin on 10 August 2022, when Mr. Calvert is temporarily suspended, and will end on 09 August 2024 at 11:59 pm.
The National Anti-Doping Panel is the independent tribunal in the UK responsible for adjudicating anti-doping disputes in sport. It is operated by Sport Resolutions and is completely independent of UK Anti-Doping, which is responsible for investigating, prosecuting and prosecuting cases before the NADP.
England v. Ashley Calvert Judgment PDF
Wednesday, 21 June 2023